Hepatitis C pharmacogenetics: State of the art in 2010

In 2009, a correlated set of polymorphisms in the region of the interleukin‐28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon‐alfa and ribavirin. The same polymorphisms were subsequently associated with spontaneous cle...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hepatology (Baltimore, Md.) Md.), 2011-01, Vol.53 (1), p.336-345
Hauptverfasser:	Afdhal, Nezam H., McHutchison, John G., Zeuzem, Stefan, Mangia, Alessandra, Pawlotsky, Jean‐Michel, Murray, Jeffrey S., Shianna, Kevin V., Tanaka, Yasuhito, Thomas, David L., Booth, David R., Goldstein, David B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents - therapeutic use Biological and medical sciences Clinical Trials as Topic Gastroenterology. Liver. Pancreas. Abdomen Hepacivirus - drug effects Hepacivirus - genetics Hepatitis Hepatitis C Hepatitis C virus Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - economics Hepatitis C, Chronic - genetics Hepatology HIV Human immunodeficiency virus Human viral diseases Humans Infectious diseases Interferon alpha-2 Interferon-alpha - therapeutic use Interferons Interleukins - genetics Liver. Biliary tract. Portal circulation. Exocrine pancreas Medical sciences Pharmacogenetics - legislation & jurisprudence Polyethylene Glycols - therapeutic use Recombinant Proteins Regulatory approval Ribavirin - therapeutic use United States United States Food and Drug Administration Viral diseases Viral hepatitis Viral Load
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In 2009, a correlated set of polymorphisms in the region of the interleukin‐28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon‐alfa and ribavirin. The same polymorphisms were subsequently associated with spontaneous clearance of HCV in untreated patients. The link between IL28B genotype and HCV clearance may impact decisions regarding initiation of current therapy, the design and interpretation of clinical studies, the economics of treatment, and the process of regulatory approval for new anti‐HCV therapeutic agents. (Hepatology 2011)
ISSN:	0270-9139 1527-3350
DOI:	10.1002/hep.24052